Realizing the Potential of Genomics across the Continuum of Precision Health Care: Proceedings of a Workshop (2023)
Chapter: References
References
Ashley, E. A. 2016. Towards precision medicine. Nature Reviews Genetics 17(9):507-522.
Bagenstos, S. R. 2016. The disability cliff. Democracy 35:55-67.
Carlos, R. C., S. Obeng-Gyasi, S. W. Cole, B. J. Zebrack, E. D. Pisano, M. A. Troester, L. Timsina, L. I. Wagner, J. A. Steingrimsson, I. Gareen, C. I. Lee, A. S. Adams, and C. H. Wilkins. 2022. Linking structural racism and discrimination and breast cancer outcomes: A social genomics approach. Journal of Clinical Oncology 40(13):1407-1413.
Chan, S. L., H. Z. W. Liew, F. Nguyen, J. Thumboo, W. C. Chow, and C. Sung C. 2021. Prescription patterns of outpatients and the potential of multiplexed pharmacogenomic testing. British Journal of Clinical Pharmacology 87(3):886-894.
Chanfreau-Coffinier, C., L. E. Hull, J. A. Lynch, S. L. DuVall, S. M. Damrauer, F. E. Cunningham, B. F. Voight, M. E. Matheny, D. W. Oslin, M. S. Icardi, and S. Tuteja. 2019. Projected prevalence of actionable pharmacogenetic variants and level A drugs prescribed among U.S. Veterans Health Administration pharmacy users. Journal of the American Medical Association Network Open 2(6):e195345.
Dewey, F. E., M. E. Grove, C. Pan, B. A. Goldstein, J. A. Bernstein, H. Chaib, J. D. Merker, R. L. Goldfeder, G. M. Enns, S. P. David, N. Pakdaman, K. E. Ormond, C. Caleshu, K. Kingham, T. E. Klein, M. Whirl-Carrillo, K. Sakamoto, M. T. Wheeler, A. J. Butte, J. M. Ford, L. Boxer, J. P. Ioannidis, A. C. Yeung, R. B. Altman, T. L. Assimes, M. Snyder, E. A. Ashley, and T. Quertermous. 2014. Clinical interpretation and implications of whole-genome sequencing. Journal of the American Medical Association 311(10):1035-1045.
Dunnenberger, H. M., K. R. Crews, J. M. Hoffman, K. E. Caudle, U. Broeckel, S. C. Howard, R. J. Hunkler, T. E. Klein, W. E. Evans, and M. V. Relling. 2015. Preemptive clinical pharmacogenetics implementation: Current programs in five U.S. medical centers. Annual Review of Pharmacology and Toxicology 55:89-106.
Fleisher, L. A., and J. D. Blum. 2022. A Vision of Medicare coverage for new and emerging technologies—A consistent process to foster innovation and promote value. Journal of the American Medical Association Internal Medicine. Published online October 12, 2022.
Fridley, B. L., G. D. Jenkins, A. Batzler, L. Wang, Y. Ji, F. Li, and R. M. Weinshilboum. 2010. Multivariate models to detect genomic signatures for a class of drugs: Application to thiopurines pharmacogenomics. Pharmacogenomics Journal 12:105-110.
Gorzynski, J. E., S. D. Goenka, K. Shafin, T. D. Jensen, D. G. Fisk, M. E. Grove, E. Spiteri, T. Pesout, J. Monlong, G. Baid, J. A. Bernstein, S. Ceresnak, P. C. Chang, J. W. Christle, H. Chubb, K. P. Dalton, K. Dunn, D. R. Garalde, J. Guillory, J. W. Knowles, A. Kolesnikov, M. Ma, T. Moscarello, M. Nattestad, M. Perez, M. R. Z. Ruzhnikov, M. Samadi, A. Setia, C. Wright, C. J. Wusthoff, K. Xiong, T. Zhu, M. Jain, F. J. Sedlazeck, A. Carroll, B. Paten, and E. A. Ashley. 2022. Ultrarapid nanopore genome sequencing in a critical care setting. New England Journal of Medicine 386(7):700-702.
Green, E. 2023. Exome. genome.gov/genetics-glossary/Exome (accessed February 6, 2023).
Haidar, C. E., K. R. Crews, J. M. Hoffman, M. V. Relling, and K. E. Caudle. 2022. Advancing pharmacogenomics from single-gene to preemptive testing. Annual Review of Genomics and Human Genetics 23:449-473.
Halley, M. C., E. A. Ashley, and H. K. Tabor. 2022a. Supporting undiagnosed participants when clinical genomics studies end. Nature Genetics 54(8):1063-1065.
Halley, M. C., H. S. Smith, E. A. Ashley, A. J. Goldenberg, and H. K. Tabor. 2022b. A call for an integrated approach to improve efficiency, equity, and sustainability in rare disease research in the United States. Nature Genetics 54(3):219-222.
Hebert, A., A. Simons, J. H. M. Schuurs-Hoeijmakers, H. J. P. M. Koenen, E. Zonneveld-Huijssoon, S. S. V. Henriet, E. J. H. Schatorjé, E. P. A. H. Hoppenreijs, E. K. S. M. Leenders, E. J. M. Janssen, G. W. E. Santen, S. A. de Munnik, S. V. van Reijmersdal, E. van Rijssen, S. Kersten, M. G. Netea, R. L. Smeets, F. L. van de Veerdonk, A. Hoischen, and C. I. van der Made. 2022. Trio-based whole exome sequencing in patients with suspected sporadic inborn errors of immunity: A retrospective cohort study. eLife 11:e78469.
Hoffman, J. M., C. E. Haidar, M. R. Wilkinson, K. R. Crews, D. K. Baker, N. M. Kornegay, W. Yang, C. H. Pui, U. M. Reiss, A. H. Gaur, S. C. Howard, W. E. Evans, U. Broeckel, and M. V. Relling. 2014. PG4KDS: A model for the clinical implementation of pre-emptive pharmacogenetics. American Journal of Medical Genetics Part C: Seminars in Medical Genetics 166C(1):45-55.
Ibañez, K., J. Polke, R. T. Hagelstrom, E. Dolzhenko, D. Pasko, E. R. A. Thomas, L. C. Daugherty, D. Kasperaviciute, K. R. Smith; WGS for Neurological Diseases Group, Z. C. Deans, S. Hill, T. Fowler, R. H. Scott, J. Hardy, P. F. Chinnery, H. Houlden, A. Rendon, M. J. Caulfield, M. A. Eberle, R. J. Taft, A. Tucci, and the Genomics England Research Consortium. 2022. Whole genome sequencing for the diagnosis of neurological repeat expansion disorders in the UK: A retrospective diagnostic accuracy and prospective clinical validation study. Lancet Neurology 21(3):234-245.
IOM (Institute of Medicine). 2003. Unequal treatment: Confronting racial and ethnic disparities in health care. Washington, DC: The National Academies Press.
IOM. 2013. The economics of genomic medicine: Workshop summary. Washington, DC: The National Academies Press.
IOM and NRC (National Research Council). 2011. Direct-to-consumer genetic testing: Summary of a workshop. Washington, DC: The National Academies Press.
Kim, D. S., L. Wiel, and E. A. Ashley. 2022. Mind the gap: The complete human genome unlocks benefits for clinical genomics. Clinical Chemistry, hvac133.
Kimpton, J. E., I. M. Carey, C. J. D. Threapleton, A. Robinson, T. Harris, D. G. Cook, S. DeWilde, and E. H. Baker. 2019. Longitudinal exposure of English primary care patients to pharmacogenomic drugs: An analysis to inform design of pre-emptive pharmacogenomic testing. British Journal of Clinical Pharmacology 85(12):2734-2746.
Kuch, W., C. Rinner, W. Gall, and M. Samwald. 2016. How many patients could benefit from pre-emptive pharmacogenomic testing and decision support? A retrospective study based on nationwide Austrian claims data. Studies in Health Technology and Informatics 223:253-258.
Kwon, D. H., H. T. Borno, H. H. Cheng, A. Y. Zhou, and E. J. Small. 2020. Ethnic disparities among men with prostate cancer undergoing germline testing. Urologic Oncology 38(3):80.e1-80.e7.
Lewis, A. C. F., S. J. Molina, P. S. Appelbaum, B. Dauda, A. Di Rienzo, A. Fuentes, S. M. Fullerton, N. A. Garrison, N. Ghosh, E. M. Hammonds, D. S. Jones, E. E. Kenny, P. Kraft, S. S. Lee, M. Mauro, J. Novembre, A. Panofsky, M. Sohail, B. M. Neale, and D. S. Allen. 2022. Getting genetic ancestry right for science and society. Science 376(6590):250-252.
Miller, N. A., E. G. Farrow, M. Gibson, L. K. Willig, G. Twist, B. Yoo, T. Marrs, S. Corder, L. Krivohlavek, A. Walter, J. E. Petrikin, C. J. Saunders, I. Thiffault, S. E. Soden, L. D. Smith, D. L. Dinwiddie, S. Herd, J. A. Cakici, S. Catreux, M. Ruehle, and S. F. Kingsmore. 2015. A 26-hour system of highly sensitive whole genome sequencing for emergency management of genetic diseases. Genome Medicine 7:100.
Moore, G. 1965. Cramming more components onto integrated circuits. Electronics 38(8).
NASEM (National Academies of Sciences, Engineering, and Medicine). 2018. Implementing and evaluating genomic screening programs in health care systems: Proceedings of a workshop. Washington, DC: The National Academies Press.
NASEM. 2022. Measuring sex, gender identity, and sexual orientation. Washington, DC: The National Academies Press.
Ndugga-Kabuye, M. K., and R. B. Issaka. 2019. Inequities in multi-gene hereditary cancer testing: Lower diagnostic yield and higher VUS rate in individuals who identify as Hispanic, African, or Asian and Pacific Islander as compared to European. Familial Cancer 18(4):465-469.
Nguyen, J. Q., K. R. Crews, B. T. Moore, N. M. Krnegay, D. K. Baker, M. Hasan, P. K. Campbell, S. M. Dean, M. V. Relling, J. M. Hoffman, and C. E. Haidar. 2022. Clinician adherence to pharmacogenomics prescribing recommendations in clinical decision support alerts. Journal of the American Medical Informatics Association ocac187.
Popejoy, A. B., and S. M. Fullerton. 2016. Genomics is failing on diversity. Nature 538(7624):161-164.
Priest, J. R., S. R. Ceresnak, F. E. Dewey, L. E. Malloy-Walton, K. Dunn, M. E. Grove, M. V. Perez, K. Maeda, A. M. Dubin, and E. A. Ashley. 2014. Molecular diagnosis of long QT syndrome at 10 days of life by rapid whole genome sequencing. Heart Rhythm 11(10):1707-1713.
Quansah, E., and N. W. McGregor. 2018. Towards diversity in genomics: The emergence of neurogenomics in Africa? Genomics 110(1):1-9.
Roberts, M. E., L. R. Susswein, W. J. Cheng, N. J. Carter, A. C. Carter, R. T. Klein, K. S. Hruska, and M. L. Marshall. 2020. Ancestry-specific hereditary cancer panel yields: Moving toward more personalized risk assessment. Journal of Genetic Counseling 29(4):598-606.
Samwald, M., H. Xu, K. Blagec, P. E. Empey, D. C. Malone, S. M. Ahmed, P. Ryan, S. Hofer, and R. D. Boyce. 2016. Incidence of exposure of patients in the United States to multiple drugs for which pharmacogenomic guidelines are available. PLoS One 11(10):e0164972.
Saunders, C. J., N. A. Miller, S. E. Soden, D. L. Dinwiddie, A. Noll, N. A. Alnadi, N. Andraws, M. L. Patterson, L. A. Krivohlavek, J. Fellis, S. Humphray, P. Saffrey, Z. Kingsbury, J. C. Weir, J. Betley, R. J. Grocock, E. H. Margulies, E. G. Farrow, M. Artman, N. P. Safina, J. E. Petrikin, K. P. Hall, and S. F. Kingsmore. 2012. Rapid whole-genome sequencing for genetic disease diagnosis in neonatal intensive care units. Science Translational Medicine 4(154):154ra135.
Schildcrout, J. S., J. C. Denny, E. Bowton, W. Gregg, J.M. Pully, M. A. Basford, J. D. Cowan, H. Xu, A. H. Ramirez, D. C. Crawford, M. D. Ritchie, J. F. Peterson, D. R. Masys, R. A. Wilke, and D. M. Roden. 2012. Optimizing drug outcomes through pharmacogenetics: A case for preemptive genotyping. Clinical Pharmacology & Therapeutics 92(2):235-242.
Shchelochkov, O. A. 2023. Gigabase (GB). https://www.genome.gov/genetics-glossary/Gigabase#:~:text=A%20gigabase%20(abbreviated%20Gb)%20is,equal%20to%201%20billion%20bases (accessed February 3, 2023).
Sirugo, G., S. M. Williams, and S. A. Tishkoff. 2019. The missing diversity in human genetic studies. Cell 177(1):26-31.
Slatko, B. E., A. F. Gardner, and F. M. Ausubel. 2018. Overview of next-generation sequencing technologies. Current Protocols in Molecular Biology 122(1):e59.
Spencer, J. 2019. How much is the average PTO in the U.S.? https://www.zenefits.com/workest/how-much-is-average-pto-in-the-us/ (accessed December 29, 2022).
Splinter, K., D. R. Adams, C. A. Bacino, H. J. Bellen, J. A. Bernstein, A. M. Cheatle-Jarvela, C. M. Eng, C. Esteves, W. A. Gahl, R. Hamid, H. J. Jacob, B. Kikani, D. M. Koeller, I. S. Kohane, B. H. Lee, J. Loscalzo, X. Luo, A. T. McCray, T. O. Metz, J. J. Mulvihill, S. F. Nelson, C. G. S. Palmer, J. A. Phillips 3rd, L. Pick, J. H. Postlethwait, C. Reuter, V. Shashi, D. A. Sweetser, C. J. Tifft, N. M. Walley, M. F. Wangler, M. Westerfield, M. T. Wheeler, A. L. Wise, E. A. Worthey, S. Yamamoto, and E. A. Ashley; for the Undiagnosed Diseases Network. 2018. Effect of genetic diagnosis on patients with previously undiagnosed disease. New England Journal of Medicine 379(22):2131-2139.
Zeitler, E. P., L. G. Gilstrap, M. Coylewright, D. J. Slotwiner, C. H. Colla, and S. M. Al-Khatib. 2022. Coverage with evidence development: Where are we now? American Journal of Managed Care 28(8):382-389.
